Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study

Objectives: This phase IIIB study compared the efficacy and safety of febuxostat and allopurinol in gout patients with or without tophi who were HLA-B*5801 negative. Method: Eligible patients were randomized to a febuxostat group (80 mg QD) or an allopurinol group (300 mg QD). Following an initial 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, K-H, Lai, J-H, Hsu, P-N, Chen, D-Y, Chen, C-J, Lin, H-Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898137/
https://www.ncbi.nlm.nih.gov/pubmed/26771445
http://dx.doi.org/10.3109/03009742.2015.1099729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898137/
https://www.ncbi.nlm.nih.gov/pubmed/26771445
http://dx.doi.org/10.3109/03009742.2015.1099729

Ejemplares similares